News | February 26, 2015

Massachusetts Breast Surgeon Presenting on BioZorb Surgical Marker at International Conference

Three-dimensional device helps track tumor site after lumpectomy for more precise radiation treatment

BioZorb, Focal Therapeutics, breast cancer, Schonholz, conference

Steven Schonholz, M.D., FACS, breast surgeon and director of the Center for Comprehensive Breast Health at Noble Hospital, stands in one of the exam rooms.

February 26, 2015 — A Noble Hospital breast surgeon's work with a new device that improves treatment of breast cancers will be featured later this month at a prestigious international medical conference.

Steven Schonholz, M.D., FACS, will present a scientific poster at the 32nd annual Miami Breast Cancer Conference, in Miami Beach, Fla., Feb. 26 to March 1. Schonholz will focus on BioZorb, a novel three-dimensional bioabsorbable surgical marker which helps physicians track the tumor site after lumpectomy surgery to remove cancer and deliver more precise radiation treatment.

Schonholz was the first physician in Massachusetts to use BioZorb as part of his medical practice. He is director of the Center for Comprehensive Breast Health at Noble Hospital.

BioZorb contains several tiny titanium clips positioned in a 3-D pattern inside a bioabsorbable coil. The body eventually resorbs the coil, leaving the titanium clips for long-term visualization of the surgery site.

"This unique device does a better job of helping us protect healthy tissue around the surgical site during radiation therapy," said Schonholz. "It can also provide our patients with a more satisfying cosmetic result after treatment."

The work by Schonholz that is being recognized at the Miami conference includes an infographic explaining how BioZorb is used in the treatment of breast cancer. Among advantages of the marker that are outlined in the infographic are these:

  • It is readily placed by the surgeon and can be easily visualized.
  • It helps target the radiation therapy to a smaller target area which results in less radiation to normal tissues.
  • It provides a stable 3-D identification of where the tumor was prior to removal, to help with treatment and longer-term follow-up.

 

Preliminary experience suggests the BioZorb infographic effectively informs patients and clinicians about an advanced tissue marking method and improves communication between the breast surgeon and radiation oncologist, according to the poster.

For more information: www.noblehospital.org

Related Content

Transpara Deep Learning Software Matches Experienced Radiologists in Mammogram Reading
News | Computer-Aided Detection Software | January 12, 2018
Deep learning and artificial intelligence improves the efficiency and accuracy of reading mammograms, according to...
Fat Distribution in Women and Men Provides Clues to Heart Attack Risk
News | Women's Health | January 11, 2018
January 11, 2018 – It’s not the amount of fat in your body but where it is stored that may increase your risk for hea
Women Prefer Getting Mammograms Every Year
News | Mammography | January 09, 2018
Women prefer to get their mammograms every year, instead of every two years, according to a new study presented at the...
Planmed Clarity 2-D Digital Mammography System Receives FDA Approval
Technology | Mammography | January 08, 2018
The U.S. Food and Drug Administration (FDA) issued an approval letter for the Planmed Clarity 2-D full-field digital...
Overweight Women May Need More Frequent Mammograms
News | Mammography | January 04, 2018
Women with higher body mass index (BMI) face an increased risk of not detecting their breast tumor until it has become...
About 25 percent of screening patients and 60 percent of diagnostic patients do not have prior mammograms available for comparison at the time of their examinations due to the lack of interoperability or other restrictions preventing clinicians from accessing prior exams.

About 25 percent of screening patients and 60 percent of diagnostic patients do not have prior mammograms available for comparison at the time of their examinations due to the lack of interoperability or other restrictions preventing clinicians from accessing prior exams.

Feature | Breast Imaging | January 02, 2018 | Kathryn Pearson Peyton, M.D.
Sixty million women undergo regular screening mammography in the United States, but even in the digital age, it is di
Imagio Opto-Acoustic Breast Imaging System Helps Differentiate Tumor Subtypes
News | Oncology Diagnostics | January 02, 2018
Seno Medical Instruments Inc. (Seno Medical) recently reported data from their clinical study demonstrating that its...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
Overlay Init